However, the discovery that anti-AQP4 IgG antibodies were present in serum of patients with NMO[4] has revolutionized the diagnosis criteria for this disease and allows more specific treatments that may help reduce the frequency of new relapses. This evidence concerns the gene AQP4 and neuromyelitis optica.